新冠疫苗心肌炎安全信号研究的方法学异质性与质量系统评价
该系统评价纳入30项观察性研究(35个设计特异性分析),评估新冠疫苗接种后心肌炎风险研究的方法学质量与异质性来源。研究发现风险窗口长度(7-288天)、参照期设置和新冠感染控制方式存在较大变异,37%的分析总体偏倚风险为严重或极严重。Meta回归显示28天风险窗口的效应估计比7天低0.56倍(95%CI 0.43-0.72),但设计选择对异质性的解释仍不明确。
要点
- 新冠疫苗心肌炎观察性研究的风险窗口、参照期和混杂控制方法差异大。
- 37%的设计特异性分析总体偏倚风险为严重或极严重。
- 28天风险窗口效应估计比7天低0.56倍(95%CI 0.43-0.72)。
核心结论
- 新冠疫苗心肌炎安全信号研究的设计规格存在实质性变异,报告效应估计异质性大。
- 风险窗口长度等设计选择可能解释部分异质性,但证据尚不确定。
- 未来疫苗安全性研究应包含敏感性分析以探索设计选择对结果的影响。
研究设计与样本
- 共纳入30项研究,包含35个设计特异性分析。
- 使用ROBINS-I工具评估偏倚风险,对可比PICO问题的研究进行Meta分析和多变量Meta回归。
主要发现
- 设计要素变异包括风险窗口长度7-288天、参照期设置三种方式、新冠感染控制五种方法。
- 一般人群中第二剂BNT162b2与未接种/参照期比较异质性最强(I2=96%,预测区间0.40-20.20)。
- 第二剂mRNA-1273与未接种/参照期比较异质性亦强(I2=92%,预测区间1.23-88.63)。
- Meta回归中调整年龄和性别后,28天风险窗口样本效应估计为7天窗口的0.56倍(95%CI 0.43-0.72),但总体效应不显著。
关键数值与推荐
- 风险窗口长度范围7-288天。
- 37%的设计特异性分析总体偏倚风险为严重或极严重。
- 28天风险窗口效应估计为7天窗口的0.56倍(95%CI 0.43-0.72)。
- 第二剂BNT162b2比较异质性I2=96%,预测区间0.40-20.20。
- 第二剂mRNA-1273比较异质性I2=92%,预测区间1.23-88.63。
临床怎么用
- 解读新冠疫苗心肌炎风险研究时需关注风险窗口、参照期和混杂控制等设计差异。
- 疫苗安全性研究应报告敏感性分析以评估设计选择对效应估计的影响。
局限性
- 设计选择对异质性的解释证据尚不确定。
- 研究设计、结局定义、新冠感染处理方式和总体偏倚风险在Meta回归中效应不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of myocarditis following COVID-19 vaccines has been widely investigated, yielding highly variable effect estimates. It remains unclear how much of this variation can be explained by methodological differences and study quality. This study aimed to evaluate the methodology of observational studies on myocarditis risk post-COVID-19 vaccination and identify sources of heterogeneity. METHODS: We systematically searched PubMed and EMBASE for observational studies reporting relative risks of myocarditis after COVID-19 vaccination published between December 2020 and October 2023. Risk of Bias (RoB) was assessed using the ROBINS-I tool. Meta-analysis and multivariable meta-regression were conducted for studies addressing comparable population-intervention-comparator-outcome (PICO) questions. RESULTS: We included 30 studies, comprising 35 design-specific analyses. We identified considerable variability in design elements including risk window length (7-288 days), reference period timing (three different ways), and control for COVID-19 disease (five different approaches). Thirteen (37%) design-specific analyses had serious or critical overall RoB. We observed strongest heterogeneity between studies in general population for dose 2 of BNT162b2 and mRNA-1273 compared to unvaccinated individuals/reference period (I2 = 96%, prediction interval (PI) of relative risk 0.40-20.20; I2 = 92%, PI 1.23-88.63, respectively). Meta-regression for the former PICO indicated that after adjusting for age and sex, effect estimates of samples with 28-day risk window were 0.56 times (95% CI 0.43-0.72) lower than those with 7-day risk window, but its overall effect was not significant. The effect of study design, outcome definition, approaches to handle COVID-19 infection and overall RoB were not significant in the meta-regression. CONCLUSIONS: There is substantial variation in study design specifications and corresponding heterogeneity in reported effect estimates. Design choices like risk window length may explain some of this heterogeneity, although evidence remains inconclusive. Future vaccine safety studies should include sensitivity analyses to explore the effect of design choices on their findings.
引用
- Trang TPH, Bazelier MT, Klungel OH, et al. Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression. Vaccine. 2026. PMID: 42142525. doi:10.1016/j.vaccine.2026.128722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。